ResearcherFred and Pamela Buffett Cancer CenterNo recent work listed

Yongji Zeng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1184-1900; OpenAlex author ID A5051946657. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2022: 1 paper

Papers 1

MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02399-3 ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tuo Hu · 1 shared paper, 2022 · strength 0.14
- Paper MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. DOI 10.1038/s41388-022-02399-3 ↗
Yi Xiao · 1 shared paper, 2022 · strength 0.14
- Paper MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. DOI 10.1038/s41388-022-02399-3 ↗
Jixin Dong · 1 shared paper, 2022 · strength 0.14
- Paper MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. DOI 10.1038/s41388-022-02399-3 ↗
Pankaj Kumar Singh · 1 shared paper, 2022 · strength 0.14
- Paper MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. DOI 10.1038/s41388-022-02399-3 ↗
Feng Yin · 1 shared paper, 2022 · strength 0.14
- Paper MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. DOI 10.1038/s41388-022-02399-3 ↗
Surinder K. Batra · 1 shared paper, 2022 · strength 0.14
- Paper MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. DOI 10.1038/s41388-022-02399-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.